Skip to main content
. 2014 Oct;13(5):427–434. doi: 10.7785/tcrtexpress.2013.600265

Figure 1:

Figure 1:

Fluorescence intensities (tumor – contralateral side) over the observation period of 48 h, including two injection points at times 0 and 24 h: (A) BT-474 and (B) MD-MBA-361.